This Insider Has Just Sold Shares In Vir Biotechnology

We note that the Vir Biotechnology, Inc. (NASDAQ:VIR) Executive VP, Vanina de Verneuil, recently sold US$42k worth of stock for US$11.18 per share. However we note that the sale only shrunk their holding by 3.3%.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Vir Biotechnology Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider sale was by the Independent Chairman, Vicki Sato, for US$221k worth of shares, at about US$10.05 per share. That means that an insider was selling shares at slightly below the current price (US$11.02). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. However, while insider selling is sometimes discouraging, it's only a weak signal. It is worth noting that this sale was only 2.0% of Vicki Sato's holding.

Insiders in Vir Biotechnology didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

View our latest analysis for Vir Biotechnology

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Does Vir Biotechnology Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. It appears that Vir Biotechnology insiders own 4.2% of the company, worth about US$79m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Vir Biotechnology Insiders?

Our data shows a little more insider selling, but no insider buying, in the last three months. However, the sales are not big enough to concern us at all. We're a little cautious about the insider selling at Vir Biotechnology. But we do like the fact that insiders own a fair chunk of the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For instance, we've identified 3 warning signs for Vir Biotechnology (1 makes us a bit uncomfortable) you should be aware of.

Of course Vir Biotechnology may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.